Tessera
Folgen

Jeffrey Peppercorn MD

@ethicsdoctorp.bsky.social

Oncologist and Bioethicist with interest in health policy and rock n roll. Editor-in-Chief JCO Oncology Practice.

21 Posts731 Follower109 Folgt
News Medical@newsmedical.bsky.social · 3mo ago

GLP-1 drugs, known for weight loss and diabetes, may lower breast cancer risk by nearly 30% in women, says a new study. 👀✨ www.news-medical.net/news/2026060... #BreastCancer #GLP1 @ascocancer.bsky.social

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 expo...

news-medical.net

Hannah R. Abrams@hannahrabrams.bsky.social · 9mo ago

Woah! 41% of stage I/IIA dMMR colon cancers could be overstaged by CT imaging. May need better ways to upfront stage (MRI, ctDNA?) in the neoadjuvant ICI era. #GIOnc #OncSky #MedSky #JCOOP ascopubs.org/doi/10.1200/...

Accuracy of Computed Tomography Staging of Mismatch Repair-Deficient Colon Cancer | JCO Oncology Practice

PURPOSEThis study assesses the accuracy of radiographic clinical staging by computed tomography (CT) of mismatch repair-deficient (dMMR) colon cancer, given emerging data for neoadjuvant immune…

ascopubs.org

Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy | JCO Oncology Practice

PURPOSEImmune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyro...

ascopubs.org

Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Another great #ASCO25 Also wonderful to see my amazing JCO Oncology Practice colleagues! 📝 Loved Dr. DeMichele’s discussion of SERENA-6 and the incredible CHALLENGE trial data for exercise in colon cancer survivors. 🏃‍♂️ And a chance to hang out for a few hours with my daughter! 🥰

Bild
Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | JCO Oncology Practice

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...

ascopubs.org

Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Patient, Parent, and Oncologist Perspectives and Recommendations on the Right Way to Talk About Prognosis in Advanced Childhood Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Patient, Parent, and Oncologist Perspectives and Recommendations on the Right Way to Talk About Prognosis in Advanced Childhood Cancer | JCO Oncology Practice

PURPOSEClear prognostic communication is associated with improvements in quality of life and suffering for children with advanced illness. Yet recent evidence demonstrates that pediatric oncologists o...

ascopubs.org

Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Reducing Medicare Part D Out-of-Pocket Costs for Specialty Oral Anticancer Drugs Under the Inflation Reduction Act: Highlighting the Benefits of Enrolling in the Medicare Prescription Payment Plan | J...

PURPOSEMedicare Part D beneficiaries who do not qualify for low-income subsidies face high out-of-pocket (OOP) costs for brand-name specialty oral anticancer medications (SOAMs). We calculated how OOP...

ascopubs.org

Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Opportunities for Artificial Intelligence in Oncology: From the Lens of Clinicians and Patients | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Opportunities for Artificial Intelligence in Oncology: From the Lens of Clinicians and Patients | JCO Oncology Practice

Much work has been published on artificial intelligence (AI) and oncology, with many focusing on an algorithm perspective. However, very few perspective articles have explicitly discussed the role of ...

ascopubs.org

Jeffrey Peppercorn MD@ethicsdoctorp.bsky.social · last yr.

Facilitated Versus Patient-Directed Advance Care Planning Among Patients With Advanced Cancer: A Randomized Clinical Trial | JCO Oncology Practice ascopubs.org/doi/10.1200/...

Facilitated Versus Patient-Directed Advance Care Planning Among Patients With Advanced Cancer: A Randomized Clinical Trial | JCO Oncology Practice

PURPOSEGuidelines recommend advance care planning (ACP) to improve patient-centered care near the end of life (EOL), but the optimal approach is unknown. This single-blind, patient-level, randomized c...

ascopubs.org